Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
/in Dendritic Cells, International Publications /von 2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)Dendritic cell immunotherapy for glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-3Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective
/in Dendritic Cells, International Publications /von 2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-70The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines
/in Hyperthermia, International Publications /von 2014-05-13 / J Clin Biochem Nutr 2014 Jul;55(1):56-61Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
/in Dendritic Cells, Glioblastoma, International Publications /von 2014-05-13 / J Immunother Cancer 2014;2:10Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen /von 2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer
/in International Publications, Newcastle Disease Virus, NSCLC /von 2014-05-12 / Virol. J. 2014 May;11:84The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2014-05-07 / J Ovarian Res 2014 May;7:48
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution